JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

Search

Maravai LifeSciences Holdings Inc (Class A)

Закрыт

3.42 -0.87

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

3.39

Макс.

3.42

Ключевые показатели

By Trading Economics

Доход

-17M

-70M

Продажи

547K

47M

Рентабельность продаж

-147.345

Сотрудники

560

EBITDA

-17M

-66M

Рекомендации

By TipRanks

Рекомендации

Покупка

Прогноз на 12 месяцев

+36.95% upside

Дивиденды

By Dow Jones

Следующий отчет о доходах

6 нояб. 2025 г.

Рыночная статистика

By TradingEconomics

Рыночная капитализация

455M

1.2B

Предыдущая цена открытия

4.29

Предыдущая цена закрытия

3.42

Техническая оценка

By Trading Central

Уверенность

Bullish Evidence

Maravai LifeSciences Holdings Inc (Class A) График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

26 окт. 2025 г., 23:52 UTC

Обсуждения рынка

Global Equities Roundup: Market Talk

26 окт. 2025 г., 23:52 UTC

Обсуждения рынка

Nikkei May Rise on Weaker Yen -- Market Talk

26 окт. 2025 г., 23:46 UTC

Обсуждения рынка

Oil Rises Amid Ongoing Supply Concerns -- Market Talk

26 окт. 2025 г., 23:41 UTC

Обсуждения рынка

Gold Falls; U.S.-China Trade Deal Optimism Overcomes Signs of Cooler U.S. Inflation -- Market Talk

26 окт. 2025 г., 23:34 UTC

Отчет

Sinopharm Group 9-Mos Oper Pft CNY10.87B Vs. Pft CNY10.84B >1099.HK

26 окт. 2025 г., 23:32 UTC

Отчет

Sinopharm Group 9-Mos Net CNY5.31B Vs. Net CNY5.28B >1099.HK

26 окт. 2025 г., 23:30 UTC

Отчет

Sinopharm Group 9-Mos Rev CNY431.48B Vs. CNY442.42B >1099.HK

26 окт. 2025 г., 22:29 UTC

Отчет

WuXi AppTec 3Q Rev CNY12.06B ; up 15.3% on Year>603259.SH

26 окт. 2025 г., 22:29 UTC

Отчет

WuXi AppTec: Higher Contributions From Contract Research Development and Manufacturing Organization Unit Supported Results>603259.SH

26 окт. 2025 г., 22:29 UTC

Отчет

WuXi AppTec: Results Also Boosted From Divestment Gains >603259.SH

26 окт. 2025 г., 22:29 UTC

Отчет

WuXi AppTec 3Q Net CNY5.13B ; up 82.9% on Year>603259.SH

26 окт. 2025 г., 22:16 UTC

Отчет

Stock Futures Rise Ahead of Mag 7 Earnings, Fed Decision -- Barrons.com

26 окт. 2025 г., 21:33 UTC

Приобретения, слияния, поглощения

Novartis Agrees to Acquire Avidity Biosciences for $12 Billion -- WSJ

26 окт. 2025 г., 19:29 UTC

Приобретения, слияния, поглощения

Novartis Deal Values Avidity Biosciences At $12 Billion -- Barrons.com

26 окт. 2025 г., 06:39 UTC

Отчет

CITIC Securities 3Q Rev CNY22.78B Vs. CNY15.96B >6030.HK

26 окт. 2025 г., 06:39 UTC

Отчет

CITIC Securities: Higher Income From Brokerage, Investment Banking Supported Results>6030.HK

26 окт. 2025 г., 06:39 UTC

Отчет

CITIC Securities 3Q Net CNY9.44B Vs. Net CNY6.23B >6030.HK

24 окт. 2025 г., 21:24 UTC

Обсуждения рынка

Global Forex and Fixed Income Roundup: Market Talk

24 окт. 2025 г., 21:24 UTC

Обсуждения рынка

Moody's Sees France With Increased Risk of Political Dysfunction -- Market Talk

24 окт. 2025 г., 21:07 UTC

Отчет

The Score: Netflix, Amazon.com, Six Flags and More Stocks That Defined the Week -- WSJ

24 окт. 2025 г., 20:58 UTC

Отчет

S&P 500 Climbs to New Record on Strong Earnings -- WSJ

24 окт. 2025 г., 20:50 UTC

Обсуждения рынка

Financial Services Roundup: Market Talk

24 окт. 2025 г., 20:40 UTC

Отчет

Intel Expects Chip Shortages on Better PC Demand. Here's Why AMD Is Winning Too. -- Barrons.com

24 окт. 2025 г., 20:24 UTC

Отчет

General Dyamics Stock Rises on Earnings. Aerospace Was a Standout. -- Barrons.com

24 окт. 2025 г., 20:23 UTC

Отчет

General Dyamics Stock Rises on Earnings. Aerospace Was a Standout. -- Barrons.com

24 окт. 2025 г., 20:13 UTC

Отчет

These Stocks Moved the Most Today: Intel, AMD, Ford, Deckers, Newmont, Nextracker, Booz Allen, Coinbase, and More -- Barrons.com

24 окт. 2025 г., 20:07 UTC

Обсуждения рынка

Different-Cell Imputation Rose Proportionally in September CPI -- Market Talk

24 окт. 2025 г., 19:40 UTC

Обсуждения рынка

Treasury Yields Mixed, Dollar Stronger Ahead of Fed Week -- Market Talk

24 окт. 2025 г., 19:35 UTC

Обсуждения рынка

Oil Rally on U.S. Russia Sanctions Loses Steam -- Market Talk

24 окт. 2025 г., 19:33 UTC

Отчет

IBM and Google Are Also Making Moves in Quantum. Don't Count Out the Bigger Players. -- Barrons.com

Сравнение c конкурентами

Изменение цены

Maravai LifeSciences Holdings Inc (Class A) Прогноз

Целевая цена

By TipRanks

36.95% рост

Прогноз на 12 месяцев

Средняя 4.67 USD  36.95%

Максимум 5 USD

Минимум 4 USD

Основано на мнении 6 аналитиков Wall Street, спрогнозировавших целевые цены для Maravai LifeSciences Holdings Inc (Class A) на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Покупка

6 ratings

4

Покупка

2

Удержание

0

Продажа

Техническая оценка

By Trading Central

2.02 / 2.115Поддержка и Сопротивление

Краткосрочная

Bullish Evidence

Среднесрочная

Strong Bullish Evidence

Долгосрочная

No Evidence

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

$

О компании Maravai LifeSciences Holdings Inc (Class A)

Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as custom enzyme development and manufacturing and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody, and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. The company was incorporated in 2020 and is headquartered in San Diego, California.
help-icon Live chat